JNJ

#20
Johnson & Johnson Common Stock
222.0 9 USD
-1.40%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
222.02
222.34
1年のレンジ
149.04
251.71
1日の変化
-1.40%
月次変化
-1.52%
6か月変化
+8.21%
1年の変化
+43.55%
以前の終値
225.2 4
Open
222.3 1
安値
222.0 2
High
222.3 4
ボリューム
214
チャート全体を表示 Full chart

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 534.62 B
  • Employee 141 K
  • Founded N/A
  • CEO Joaquin Duato
  • Website www.jnj.com
  • Headquarter New Jersey, United States
  • FIGI BBG000BMHYD1
  • Industry 医薬品メーカー（一般）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
18.82
売上高対価格比率
5.35
1株当たり配当金
5.14
配当利回り（％）
2.48

Johnson & Johnson Common Stock

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.

ニュース